Personalized Psychiatry and Neurology

Advanced search

Prevalence of non-motor disorders in Parkinson`s disease

Full Text:


(1) Background: to reveal the prevalence of non-motor disorders in Parkinson’s disease (PD), we analyzed both Russian and international studies on the issue of PD-associated non-motor disorders in Caucasian patients; (2) Methods: We have carried out a search for full-text Englishand Russian-language articles published during the last ten years (from 2010 to 2020) in PubMed, Scopus, Web of Science, Springer, Clinical case, and E-library databases using multiple versions of keywords and their combinations. (3) Results: General prevalence of PD-associated non-motor disorders proved to be high. At the same time, we did not find significant differences between the prevalence of cognitive, affective, or behavioral disorders in PD patients. However, depression was found to be more common in PD patients in the Russian Federation; (4) Conclusions: According to the results of our review, cognitive and affective disorders in PD represent the issues of major concern.


About the Authors

N. Yu. Safonova
V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology
Russian Federation

Natalia Yu. Safonova

192019 Saint-Petersburg

M. R. Sapronova
V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

Margarita R. Sapronova

660022 Krasnoyarsk

O A. Gavrilyuk
V.F. Voino-Yasenetsky Krasnoyarsk State Medical University
Russian Federation

Oksana A. Gavrilyuk

660022 Krasnoyarsk

T. E. Popova
Yakutsk Scientific Centre for Complex Medical Problems
Russian Federation

Tatiana E. Popova

677000, Yakutsk

A. A. Tappakhov
M.K. Ammosov North-Eastern Federal University
Russian Federation

Alexey A. Tappakhov

677000, Yakutsk


1. Krivonos, O.V. Organization of medical care for patients with Parkinson's disease in modern socio-economic conditions. Parkinson's disease and movement disorders. A Physician's Guide to the 3rd National Congress on Parkinson's Disease and Movement Disorders (with international participation), 2014, S. 217–220 (in Russ.).

2. Tappakhov, A.A.; Popova, T.E.; Nikolayeva, T.Ya.; Shnayder, N.A.; Petrova, M.M. Epidemiology of Parkinson's disease in the world and in Russia. Transbaikal Medical Bulletin 2016, 4, 151-159 (in Russ.).

3. Razdorskaya, V.V.; Voskresenskaya, O.N.; Yudina, G.K. Parkinson's disease in Russia: prevalence and incidence. Saratov Journal of Medical Scientific Research 2016, 3, 379-384 (in Russ.).

4. Ascherio, A.; Schwarzschild, M.A. The epidemiology of Parkinson's disease: risk factors and prevention. The Lancet Neurology. 2016, 15, 12, 1257-1272. doi:10.1016/S1474-4422(16)30230-7.

5. Tysnes, O.B.; Storstein, A. Epidemiology of Parkinson's disease. J Neural Transmission. 2017, 124, 8, 901-905. doi:10.1007/s00702-017-1686-y.

6. Hurt, C.S.; Rixon, L.; Chaudhuri, K.R.; Moss-Morris, R.; Samuel, M.; Brown, R.G. Barriers to reporting non-motor symptoms to health-care providers in people with Parkinson's. Parkinsonism Relat Disord. 2019, 1353-8020(19), 30209-3. doi: 10.1016/j.parkreldis.2019.04.014.

7. Gusev, E.I.; Gext, A.B.; Pavlov, H.A.; Popov G.R. Pharmacoeconomics of Parkinson's disease. Materials of the 1st National Congress on Parkinson's Disease and Movement Disorders 2010, 173 - 178 (in Russ.).

8. Milchakova, A.E.; Popov, G.R.; Bykov, A.V.; Gekht, A.B. Clinical and pharmacoeconomic analysis of the use of the drug piribedil (Pronoran) in the treatment of Parkinson's disease. Journal of Neurology and Psychiatry 2008, 4, 49-55 (in Russ.).

9. Kalia, L. V.; Lang, A. E. Parkinson’s disease. The Lancet. 2015; 386, 9996, 896–912. doi:10.1016/s0140-6736(14)61393-3.

10. Hustad, E.;Aasly, J.O. Clinical and Imaging Markers of Prodromal Parkinson's Disease. Front Neurol. 2020, 11, 395. doi:10.3389/fneur.2020.00395

11. Nodel, M.R.; Danilova, N.N.; Glozman, Zh.M.; Yakhno, N.N. The relationship between cognitive and emotional-affective disorders in patients with Parkinson's disease. Neurological journal 2016, 21, 6, 338-343 (in Russ.).

12. Poverennova, I.E.; Kalinin, V.A.; Mukhina, S.A. Identification of non-motor disorders in Parkinson's disease and determination of their relationship with motor disorders. Saratov Journal of Medical Scientific Research 2016, 12, 2, 281-285 (in Russ.).

13. Tappakhov, A.A.; Nikolaeva, T.Ya.; Okoneshnikova, L.T.; Petrova, A.Yu. Non-motor manifestations of Parkinson's disease in patients living in the Republic of Sakha (Yakutia). Ecology and human health in the North, a collection of scientific works of the 4th Congress with international participation 2016, 561-566.

14. Lytayev, S.A.; Susin D.S. PET diagnosis of cognitive impairment in patients with Parkinson's disease. Pediatrician 2016, 7, 1, 63-68 (in Russ.).

15. Rabadanova, E.A,; Gelpey, M.A.; Goncharova, Z.A. Non-motor symptoms of Parkinson's disease. their structure and impact on the quality of life of patients. Practical medicine 2015, 90, 5, 111-115 (in Russ.).

16. Khanova, M.N. Non-motor manifestations of Parkinson's disease. Eurasian Union of Scientists 2015, 19, 10-1, 124-126 (in Russ.).

17. Yakovleva, T.V.; Karakulova,Yu.V.; Demchuk, N.D. Comprehensive comparative psychometric testing of patients with Parkinson's disease. Modern problems of science and education 2015, 6, 85 (in Russ.).

18. Smolentseva, I.G.; Chupina, L.P.; Amosova, N.A.; Krivonos, O.V. Clinical assessment of the progression of Parkinson's disease. S.S. Korsakov Journal of Neurology and Psychiatry 2014, 14, 6-2, 36-40 (in Russ.).

19. Antonen, E.G.; Khyanikyaynen, I.V.; Kirsan, S.A.; Ancheyeva, E.G. Clinical characteristics of Parkinson's disease in the Republic of Karelia. Scientific notes of Petrozavodsk State University 2014, 145, 8-2: 41-47 (in Russ.).

20. Mazurenko, E.V. Neuroimaging criteria for diagnosis and clinical features of cognitive impairment in patients with Parkinson's disease. Medical news 2016, 4, 73-76 (in Russ.).

21. Lemprière, S. Frontotemporal dementia risk variant accelerates cognitive decline in Parkinson disease. Nature Reviews Neurology 2019, doi:10.1038/s41582-019-0196-y.

22. Shprecher, D.; Zhang, N.; Halverson, M.; Savica R. Parkinsonism Risk Factors in Salt Lake City, Utah: A Community-Based Study. Brain Sci. 2019, 9, 3, 71. doi:10.3390/brainsci9030071.

23. Chahine, L.M.; Urbe, L.; Caspell-Garcia C.; Aarsland, D.; Alcalay, R.; Barone, P.; Burn, D.; Espay, A.J.; Hamilton, J.L.; Hawkins, K.A.; Lasch, S.; Leverenz, J.B.; Litvan, I.; Richard, I.; Siderowf, A.; Coffey, C.S.; Simuni, T.; Weintraub, D. Cognition among individuals along a spectrum of increased risk for Parkinson’s disease. PLoS One. 2018, 13, 8, e0201964. doi:10.1371/journal.pone.0201964.

24. Wyman-Chick, K.A.; Martin, P.K.; Barrett, M.J.; Manning, C.A.; Sperling, S.A. Diagnostic Accuracy and Confidence in the Clinical Detection of Cognitive Impairment in Early-Stage Parkinson Disease. J Geriatr Psychiatry Neurol. 2017, 30, 3, 178-183. doi:10.1177/0891988717701001.

25. Weintraub, D.; Simuni, T.; Caspell-Garcia, C.; Coffey, C.; Lasch, S.; Siderowf, A.; Aarsland. D.; Barone, P.; Burn, D.; Chahine, L.M.; Eberling, J.; Espay, A.J.; Foster, E.D.; Leverenz, J.B.; Litvan I.; Richard, I.; Troyer, M.D.; Hawkins, K.A. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015, 30, 7, 919-927. doi:10.1002/mds.26170.

26. McDermott, K. L.; Fisher, N.; Bradford, S.; Camicioli, R. Parkinson’s disease mild cognitive impairment classifications and neurobehavioral symptoms. International Psychogeriatrics 2017, 30, 02, 253-260. doi:10.1017/s1041610217002265.

27. Lawrence, B.J.; Gasson, N.; Loftus ,A.M. Prevalence and Subtypes of Mild Cognitive Impairment in Parkinson's Disease. Sci Rep. 2016, 21, 6, 33929. doi:10.1038/srep33929.

28. Gigante, A.F.; Bruno, G.; Iliceto, G.; Guido, M.; Liuzzi, D.; Mancino, P.V.; De Caro M.F.; Livrea, P.; Defazio, G. Action tremor in Parkinson’s disease: frequency and relationship to motor and non-motor signs. Eur J Neurol. 2015, 22, 2, 223. doi:10.1111/ene.12583.

29. Galtier, I.; Nieto, A.; Lorenzo, J.N.; Barroso, J. Mild Cognitive Impairment in Parkinson's Disease: Clustering and Switching Analyses in Verbal Fluency Test. J Int Neuropsychol Soc. 2017; 23, 6, 511-520. doi: 10.1017/S1355617717000297.

30. Galtier, I.; Nieto, A.; Lorenzo, J.N.; Barroso J. Mild cognitive impairment in Parkinson's disease: Diagnosis and progression to dementia. J Clin Exp Neuropsychol. 2016, 38, 1, 40-50. doi:10.1080/13803395.2015.1087465.

31. Pfeiffer, H.C.; Løkkegaard, A; Zoetmulder, M.; Friberg, L.; Werdelin, L. Cognitive impairment in early-stage non-demented Parkinson's disease patients. Acta Neurol Scand. 2014, 129, 5, 307-318. doi:10.1111/ane.12189.

32. Cosgrove, J.; Alty, J. E.; Jamieson, S. Cognitive impairment in Parkinson’s disease. Postgraduate Medical Journal 2015, 91, 1074, 212-220. doi:10.1136/postgradmedj-2015-133247.

33. Bargiotas, P.; Ntafouli, M.; Lachenmayer, M.L.; Krack ,P.; Schüpbach, W.M.M.; Bassetti , C.L.A. Apathy in Parkinson's disease with REM sleep behavior disorder. J Neurol Sci. 2019, 15, 399, 194-198, doi:10.1016/j.jns.2019.02.028.

34. Zhukova, I.A.; Zhukova, N.G.; Alifirova, V.M.; Nikitina, M.A;. Izhboldina, O.P.. Brazovskaya, N.G. Depression and other non-motor manifestations of Parkinson's disease. Clinical medicine 2017, 95, 4, doi:10.18821/0023-2149-2017-95-5-419-424.

35. Nikitina, A.V.; Fedorova, N.V. Behavioral disorders in Parkinson's disease on the background of dopaminergic therapy. Annals of Clinical and Experimental Neurology 2017, 11, 1, 14-20 (in Russ.).

36. Nodel, M.R.; Obukhova A.V.; Yakhno N.N. he effectiveness of piribedil in neuropsychiatric disorders in the early stages of Parkinson's disease. Neurological journal 2016, 21, 2, 110-116 (in Russ.).

37. Zalyalova, Z.A.; Khasanova, D.M. Depression in patients with early stages of Parkinson's disease. Difficult patient 2016, 14, 4-5, 22-28 (in Russ.).

38. Bogdanov, R.R.; Borisova, S.Yu.; Kotov, S.V. Cognitive and affective disorders in the early stages of Parkinson's disease. Almanac of Clinical Medicine 2015, 39, 90-96 (in Russ.).

39. Akhmadeyeva, G.N.; Magzhanov, R.V. Anxiety-depressive disorders in patients with Parkinson's disease in the Republic of Bashkortostan. Ural medical journal 2015, 125, 2, 44-48 (in Russ.).

40. Fedorova, N.V.; Kulua, T.K..; Gubareva N.N. Depression in Parkinson's disease. The effectiveness of the new antidepressant valdoxan (agomelatine) in the correction of affective and dyssomnic disorders. Psychiatry and psychopharmacotherapy 2015, 17, 4, 9-14 (in Russ.).

41. De Lau, L.M.; Verbaan, D.; Marinus, J.; van Hilten, J.J. Survival in Parkinson's disease. Relation with motor and non-motor features. Parkinsonism Relat Disord. 2014, 20, 6, 613-619. doi:10.1016/j.parkreldis.2014.02.030.

42. Hughes, K.C; Gao, X.; Baker, J.M.; Stephen, C.; Kim ,I.Y.; Valeri, L.; Schwarzschild, M.A.; Ascherio, A. Non-motor features of Parkinson's disease in a nested case-control study of US men. J Neurol Neurosurg Psychiatry 2018, 89, 12, 1288-1295. doi:10.1136/jnnp-2018-318275.

43. Nodel, M.R. Anxiety in Parkinson's disease. Neurological journal 2018, 23, 4, 176-183 (in Russ.).

44. Hinkle, J.T.; Perepezko, K.; Bakker, C.C.; Dawson, T.M.; Johnson, V.; Mari, Z.; Marvel, C.L.; Mills, K.A.; Pantelyat, A.; Pletnikova, O.; Rosenthal, L.S.; Shepard, M.D.; Stevens, D.A.; Troncoso, J.C.; Wang, J.; Pontone, G.M. Domain-specific cognitive impairment in non-demented Parkinson's disease psychosis. Int J Geriatr Psychiatry 2018, 33, 1, e131-e139. doi:10.1002/gps.4736.

45. Barrett, M.J.; Smolkin, M.E.; Flanigan, J.L; Shah, B.B.; Harrison, M.B.; Sperling, S.A. Characteristics, correlates, and assessment of psychosis in Parkinson disease without dementia. Parkinsonism Relat Disord. 2017, 43, 56-60. doi:10.1016/j.parkreldis.2017.07.011.

46. Weintraub, D.; Simuni, T.; Caspell-Garcia, C.; Coffey C.; Lasch, S.; Siderowf, A., Aarsland, D., Barone, P.; Burn, D.; Chahine, L.M.; Eberling, J.; Espay, A.J.; Foster, E.D.; Leverenz, J.B.; Litvan, I.; Richard, I.; Troyer, M.D.; Hawkins, K.A. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord. 2015, 30, 7, 919-927. doi:10.1002/mds.26170.

47. Gordon, P.C.; Kauark, R.B.; Costa, C.D.; de Oliveira, M.O.; Godinho F.L; Rocha, M.S. Clinical Implications of the National Institute of Neurological Disorders and Stroke Criteria for Diagnosing Psychosis in Parkinson's Disease. J Neuropsychiatry Clin Neurosci. 2016, 28, 1, 26-31. doi:10.1176/appi.neuropsych.15050119.

48. Rana, A. Q.; Ahmed, U. S.; Chaudry, Z. M.; Vasan, S. Parkinson’s disease: a review of non-motor symptoms. Expert Review of Neurotherapeutics 2015, 15, 5, 549-562. doi:10.1586/14737175.2015.1038244.

49. Weintraub, D.; Koester, J.; Potenza, M.N.; Siderowf, A.D.; Stacy, M.; Voon, V.; Whetteckey, J.; Wunderlich, G.R.; Lang, A.E. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology 2010, 67, 5, 589-595. doi:10.1001/archneurol.2010.65. Garcia-Ruiz, P. J.; Martinez Castrillo, J. C.; Alonso-Canovas, A.; Herranz Barcenas, A.; Vela, L.; Sanchez Alonso, P.; Mahillo Fernandez, I. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. Journal of Neurology, Neurosurgery & Psychiatry 2014, 85, 8, 840-844. doi:10.1136/jnnp-2013-306787.


For citations:

Safonova N.Yu., Sapronova M.R., Gavrilyuk O.A., Popova T.E., Tappakhov A.A. Prevalence of non-motor disorders in Parkinson`s disease. Personalized Psychiatry and Neurology. 2021;1(2):117-125.

Views: 391

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2712-9179 (Online)